Zacks Investment Research upgraded shares of Intec Pharma Ltd. (NASDAQ:NTEC) from a sell rating to a hold rating in a research note issued to investors on Friday morning.

According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “

NTEC has been the topic of a number of other research reports. Oppenheimer Holdings, Inc. upped their target price on Intec Pharma from $10.00 to $15.00 and gave the company an outperform rating in a report on Thursday, September 21st. ValuEngine downgraded Intec Pharma from a hold rating to a sell rating in a report on Friday, June 9th. CIBC reiterated an outperform rating and issued a $15.00 target price (up previously from $10.00) on shares of Intec Pharma in a report on Thursday, September 21st. Finally, Roth Capital set a $10.00 target price on Intec Pharma and gave the company a buy rating in a report on Thursday, August 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Intec Pharma presently has an average rating of Buy and an average target price of $10.90.

Shares of Intec Pharma (NTEC) opened at 9.60 on Friday. The firm’s market capitalization is $131.88 million. The company has a 50 day moving average of $7.75 and a 200 day moving average of $7.75. Intec Pharma has a 52-week low of $4.20 and a 52-week high of $9.75.

TRADEMARK VIOLATION NOTICE: “Intec Pharma Ltd. (NTEC) Upgraded by Zacks Investment Research to Hold” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.watchlistnews.com/intec-pharma-ltd-ntec-upgraded-by-zacks-investment-research-to-hold/1587851.html.

An institutional investor recently raised its position in Intec Pharma stock. Migdal Insurance & Financial Holdings Ltd. grew its holdings in Intec Pharma Ltd. (NASDAQ:NTEC) by 5.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 522,200 shares of the biotechnology company’s stock after purchasing an additional 25,000 shares during the period. Migdal Insurance & Financial Holdings Ltd. owned about 3.80% of Intec Pharma worth $2,977,000 as of its most recent SEC filing. Institutional investors own 16.41% of the company’s stock.

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Get a free copy of the Zacks research report on Intec Pharma (NTEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.